A private care gel containing lysozyme

By combining lysozyme, yamolin and oxidized malphinine into a private gel and combining pharmaceutical excipients, the problems of antibacterial resistance and lack of antibacterial effect in the treatment of vaginitis are solved, and effective Bacterial and fungal inhibition and chemical stability provide a natural, non-toxic treatment option.

CN115025209BActive Publication Date: 2024-11-22HANGZHOU QINGKANG BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210666847.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-06-13
Publication Date
2024-11-22
Estimated Expiration
2042-06-13

AI Technical Summary

Technical Problem

In the prior art, the excessive use of antibacterial drugs in the treatment of vaginitis leads to resistance to pathogenic microorganisms, and the topical treatment of traditional Chinese medicine has both local and systemic effects but lacks effective natural antibacterial gel preparations.

Method used

A combination of lysozyme, yamolin and oxidized maltine, with a weight ratio of 1:(1-5):(1-5), is prepared a private gel preparation for inhibiting bacteria and fungi, and combines it with Pharmaceutical excipients such as sodium carboxymethylcellulose, poloxamer and glycerol form a stable gel matrix.

Benefits of technology

This private gel preparation significantly inhibits bacteria and fungi, has synergistic effect, improves the effectiveness and chemical stability of vaginitis treatment, and has natural and non-toxic side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003691854340000061
    Figure BDA0003691854340000061
  • Figure BDA0003691854340000062
    Figure BDA0003691854340000062
Patent Text Reader

Abstract

The present invention relates to a private protection gel preparation, wherein the weight ratio of active ingredients lysozyme, sophanthin and oxymatrine is 1:(1-5):(1-5). The preparation method of the private protection gel preparation of the present invention is simple and the quality is stable. The three active ingredients can synergistically treat gynecological diseases such as vaginitis caused by various bacteria and fungi while exerting their own effects. In addition, lysozyme, sophanthin and oxymatrine are of natural origin and have no toxic side effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medicine, and in particular to a private protection gel containing lysozyme. Background Art

[0002] Vaginitis is a group of diseases that cause vulvovaginal symptoms such as itching, burning pain, irritation and abnormal discharge. Western medicine theory believes that vaginitis is caused by dysbiosis in women's bodies. Western medicine treatment methods mostly use oral or topical antibacterial drugs to inhibit pathogenic microorganisms. For example, nitroimidazole antibiotics are commonly used for Trichomonas vaginitis, clindamycin antibiotics are commonly used in addition to nitroimidazoles for bacterial vaginitis, and azole and polyene antibiotics are commonly used for candidiasis. However, excessive use of Western medicine antibiotics can easily cause pathogenic microorganisms to develop drug resistance, causing the disease to recur.

[0003] Vaginitis belongs to the category of leukorrhea in traditional Chinese medicine. Traditional Chinese medicine believes that the cause of leukorrhea is dampness, and the root cause is spleen and kidney dysfunction. Traditional Chinese medicine uses the method of syndrome differentiation and treatment to first regulate the spleen and eliminate dampness, and then warm the kidney and consolidate the body, so as to fundamentally treat vaginitis, and the disease is not easy to recur. Studies have confirmed that external use of Chinese medicine is more effective than Western medicine, and adverse reactions are relatively rare.

[0004] Topical preparations refer to drug preparations that are directly applied to the skin and mucous membranes. They can not only play a local therapeutic role, but also be absorbed through the skin or mucous membranes into the systemic circulation to achieve the purpose of systemic treatment. At the same time, they can also reduce the irritation and adverse reactions of the drug to the gastrointestinal tract, avoid the first-pass effect of the liver, and thus improve the bioavailability of the drug. With the development of modern science and technology, new topical preparations (such as transdermal preparations and transmucosal preparations) are increasingly used in diseases such as internal medicine, gynecology, and pediatrics. In recent years, the leading dosage forms of gynecological Chinese medicine topical drugs market are lotions and suppositories, and new topical preparations of Chinese medicine for gynecology include films and gels.

[0005] Gels are semi-solid preparations with gel properties made of drugs and suitable matrices. According to the different gel matrices, they are generally divided into water-soluble gels and organic gels (or oil-soluble gels). The drugs in water-soluble gels can be dissolved in water-dispersible solvents; the drugs in organic gels should be soluble in oil-dispersible solvents. According to different preparation methods, they can be divided into environmentally sensitive gels, liposome gels, microemulsion gels, etc., and environmentally sensitive gels such as thermosensitive gels, magnetically responsive polymer gel microspheres, pH-sensitive gels and other new gels are made by using the different sensitivity of gels to physical environments such as temperature, magnetic field, and pH; the gel matrix is ​​mixed with phospholipids and cholesterol to form liposome gels with sustained release effects; the drug is mixed with a suitable aqueous phase, oil phase, and emulsifier in a certain proportion to form a microemulsion gel that can improve the solubility of poorly soluble drugs. The adhesion of the gel allows the drug to act on the affected area for a longer time, better promotes the absorption of the active ingredients and exerts the efficacy. In addition, gels can make it more convenient for patients to take medicine and improve medication compliance.

[0006] Lysozyme, also known as muramidase or N-acetylmuramin polysaccharide hydrolase, is an alkaline enzyme that can hydrolyze mucopolysaccharides in pathogenic bacteria. It mainly breaks the β-1,4 glycosidic bond between N-acetylmuramic acid and N-acetylglucosamine in the cell wall, decomposing the insoluble mucopolysaccharides in the cell wall into soluble glycopeptides, causing the cell wall to rupture and the contents to escape, thereby dissolving the bacteria.

[0007] Sophora tonkinensis is the dried root and rhizome of the leguminous plant Sophora gagnep. It is also known as Guangdougen. It is mainly distributed in Guangxi, Guizhou and other places. It has the effects of clearing away heat and detoxification, reducing swelling and relieving sore throat. Modern pharmacological studies have shown that Sophora tonkinensis has pharmacological effects such as anti-tumor, anti-viral, analgesic, anti-inflammatory, anti-liver damage, antioxidant and immune enhancement. Sophora tonkinensis contains alkaloids, flavonoids and triterpenoids. The main active ingredients include matrine, oxymatrine, cytisine, sophoracarpine, sophorol, formononetin, Vietnamese sophorol, sophora tonkinensis, sophora tonkinensis and trifoliate bean glycosides.

[0008] Oxymatrine is the main alkaloid component of Sophora flavescens, with significant anti-inflammatory, analgesic and anti-tumor effects. The results of in vivo anti-inflammatory effects confirmed that all doses of oxymatrine could reduce the swelling of mouse ears, reduce the number of acetic acid writhings in experimental mice and relieve the swelling of rat feet. Oxymatrine was injected intraperitoneally into BALB / C mice. The results showed that oxymatrine could reduce the proportion of Tfh cells in BALB / C mice, inhibit the transcription of Bcl-6mRNA in Tfh cells, reduce the secretion level of IL-21 in mice, and significantly regulate the immune function of Tfh cells. Oxymatrine was applied to mice with immune liver injury caused by ConA. The results showed that the high-dose group of oxymatrine could significantly reduce ALT activity, inhibit the expression of AST, TBIL, and CD4+IL-17A, and upregulate the proportion of CD4+CD25+FoxP3+Treg, indicating that oxymatrine has a good protective effect on ConA-induced immune liver injury in mice.

[0009] At present, there is no report on the combination of lysozyme with sophagalin and oxymatrine for use in the field of private care gel. Summary of the invention

[0010] The technical problem to be solved by the present invention is to provide a private care gel preparation which can effectively inhibit bacteria and has active ingredients derived from natural sources.

[0011] The technical solution adopted by the present invention to solve the above-mentioned problem is to provide a private protection gel preparation, wherein the weight ratio of the active ingredients lysozyme, yaconazole and oxymatrine is 1:(1-5):(1-5).

[0012] Preferably, in the privacy protection gel preparation, the weight ratio of lysozyme, yaconazole and oxymatrine is 1:(1-3):(1-3).

[0013] More preferably, in the privacy protection gel preparation, the weight ratio of lysozyme, yaconazole and oxymatrine is 1:1:2.

[0014] Preferably, the lysozyme is extracted from egg white.

[0015] Preferably, the private protection gel preparation further includes pharmaceutically acceptable excipients.

[0016] More preferably, the pharmaceutically acceptable excipient is selected from one or more of a gel matrix, a humectant, a solubilizer and a solvent.

[0017] Further preferably, the pharmaceutically acceptable excipients are gel matrix, humectant, solubilizer and solvent.

[0018] Preferably, the gel matrix is ​​selected from one or more of sodium carboxymethylcellulose, carbomer, poloxamer and hydroxypropyl methylcellulose; more preferably, the gel matrix is ​​a combination of sodium carboxymethylcellulose and poloxamer; further preferably, the gel matrix is ​​a combination of sodium carboxymethylcellulose and poloxamer 188, and the weight ratio of sodium carboxymethylcellulose and poloxamer 188 is (1-10):1; most preferably, the gel matrix is ​​a combination of sodium carboxymethylcellulose and poloxamer 188 in a weight ratio of 8:1.

[0019] Preferably, the humectant is glycerin or propylene glycol; more preferably, the humectant is glycerin.

[0020] Preferably, the solubilizing agent is Tween 80 or Tween 60; more preferably, the solubilizing agent is Tween 80.

[0021] Preferably, the solvent is distilled water.

[0022] More preferably, the pharmaceutically acceptable excipients are sodium carboxymethylcellulose, poloxamer 188, glycerol, Tween 80 and distilled water.

[0023] Further preferably, the private protection gel preparation is made of the following components in weight percentage: 0.25% lysozyme, 0.25% shantonin, 0.5% oxymatrine, 8% sodium carboxymethylcellulose, 1% poloxamer 188, 15% glycerol, 5% Tween 80 and 70% distilled water.

[0024] The second aspect of the present invention provides a method for preparing the above-mentioned private protection gel preparation, comprising the following steps:

[0025] (1) uniformly mixing lysozyme, sophanol and oxymatrine with a solubilizing agent to obtain a drug solution;

[0026] (2) adding a moisturizer to the gel matrix, mixing the mixture evenly, and then mixing the mixture evenly with the drug solution prepared in step (1);

[0027] (3) Adding a solvent to the solution obtained in step (2), stirring to make it swell, and leaving it to stand for 24 hours to obtain the product.

[0028] The third aspect of the present invention also provides the use of the above-mentioned private care gel preparation in the preparation of drugs for inhibiting bacteria and / or fungi.

[0029] Preferably, the bacteria and / or fungi are Staphylococcus aureus and / or Candida albicans.

[0030] More preferably, the present invention also provides use of the above-mentioned private protection gel preparation in the preparation of a drug for simultaneously inhibiting Staphylococcus aureus and Candida albicans.

[0031] The fourth aspect of the present invention also provides a gel matrix composition for improving the chemical stability of the above-mentioned private protection gel preparation, wherein the gel matrix composition is sodium carboxymethyl cellulose and poloxamer 188, and the weight ratio of sodium carboxymethyl cellulose and poloxamer 188 is (1-10):1.

[0032] Preferably, the weight ratio of sodium carboxymethyl cellulose to poloxamer 188 is 8:1.

[0033] Preferably, improving the chemical stability of the private protection gel preparation refers to reducing the amount of sophora japonicum and / or oxymatrine impurities generated in the preparation.

[0034] More preferably, the improvement of the chemical stability of the private protection gel preparation refers to simultaneously reducing the amount of sophora japonicum and oxymatrine impurities generated in the preparation.

[0035] The present invention has positive and beneficial effects:

[0036] Surprisingly, after repeated tests, the present invention unexpectedly found that the combination of lysozyme with sophanthin and oxymatrine has a synergistic effect on inhibiting the formation of bacteria and / or fungi. The preparation method of the private care gel preparation of the present invention is simple and the quality is stable. The three active ingredients can synergistically treat gynecological diseases such as vaginitis caused by various bacteria and fungi while exerting their own effects. In addition, lysozyme, sophanthin and oxymatrine are natural in origin and have no toxic side effects. DETAILED DESCRIPTION

[0037] The present invention will be further described below in conjunction with the examples, but the embodiments of the present invention are not limited thereto. The experimental methods used in the following examples are conventional methods unless otherwise specified. The lysozymes used in the examples and test examples are all lysozymes extracted from egg white.

[0038] Example 1, Lysozyme-containing private care gel preparation G1

[0039] Mix 0.25g of lysozyme, 0.25g of shantonin and 0.5g of oxymatrine with 5g of Tween 80 to obtain a medicinal solution; add 15g of glycerol to a mixture of 8g of sodium carboxymethyl cellulose and 1g of poloxamer 188, mix well and then mix with the medicinal solution; continue to add 70g of distilled water, stir to swell, and let stand for 24 hours to obtain the private protection gel preparation G1.

[0040] Example 2, private protection gel preparation G2 containing lysozyme

[0041] Mix 0.25g of lysozyme, 0.5g of yaconazole and 0.25g of oxymatrine with 5g of Tween 80 to obtain a medicinal solution; add 15g of glycerol to a mixture of 8g of sodium carboxymethyl cellulose and 1g of poloxamer 188, mix well and then mix with the medicinal solution; continue to add 70g of distilled water, stir to swell, and let stand for 24 hours to obtain the private protection gel preparation G2.

[0042] Example 3, private protection gel preparation G3 containing lysozyme

[0043] Mix 0.25g of lysozyme, 0.6g of yaconazole and 0.15g of oxymatrine with 5g of Tween 80 to obtain a medicinal solution; add 15g of glycerol to a mixture of 8g of sodium carboxymethyl cellulose and 1g of poloxamer 188, mix well and then mix with the medicinal solution; continue to add 70g of distilled water, stir to swell, and let stand for 24 hours to obtain the private protection gel preparation G3.

[0044] Example 4, private protection gel preparation G4 containing lysozyme

[0045] Mix 0.25g of lysozyme, 0.25g of yaconazole and 0.5g of oxymatrine with 5g of Tween 80 to obtain a medicinal solution; add 15g of glycerol to a mixture of 4.5g of sodium carboxymethyl cellulose and 4.5g of poloxamer 188, mix well and then mix with the medicinal solution; continue to add 70g of distilled water, stir to swell, and let stand for 24 hours to obtain the private protection gel preparation G4.

[0046] Example 5, private care gel preparation G5 containing lysozyme

[0047] Mix 0.25g of lysozyme, 0.25g of shantonin and 0.5g of oxymatrine with 5g of Tween 80 to obtain a medicinal solution; add 15g of glycerol to a mixture of 2g of sodium carboxymethyl cellulose and 7g of poloxamer 188, mix well and then mix with the medicinal solution; continue to add 70g of distilled water, stir to swell, and let stand for 24 hours to obtain the private protection gel preparation G5.

[0048] Comparative Example 1: Lysozyme-containing private care gel preparation C1

[0049] Mix 0.25g of lysozyme, 0.25g of yaconin and 0.5g of oxymatrine with 5g of Tween 80 to obtain a medicinal solution; add 15g of glycerol to 9g of sodium carboxymethyl cellulose, mix well and then mix with the medicinal solution; continue to add 70g of distilled water, stir to swell, and let stand for 24 hours to obtain the private protection gel preparation C1.

[0050] Comparative Example 2, Lysozyme-containing private care gel preparation C2

[0051] Mix 0.25g of lysozyme, 0.25g of yaconin and 0.5g of oxymatrine with 5g of Tween 80 to obtain a medicinal solution; add 15g of glycerol to a mixture of 8g of sodium carboxymethyl cellulose and 1g of poloxamer 407, mix well and then mix with the medicinal solution; continue to add 70g of distilled water, stir to swell, and let stand for 24 hours to obtain the private protection gel preparation C2.

[0052] Test Example 1: Efficacy of the private care gel preparation of the present invention in treating bacterial and fungal vaginitis in rabbits

[0053] 1. Test methods

[0054] 1.1. Establishment of vaginitis model

[0055] After flushing the rabbit vagina three times with 0.01ml / L phosphate buffer, 0.2ml of Staphylococcus aureus suspension was injected into the rabbit cervix through the catheter once a day for three consecutive days. The swelling and redness of the vulva and vagina, as well as the presence of secretions, were checked. Vaginal swabs were taken to obtain vaginal and cervical secretions for smear staining and microscopic examination. Obvious edema occurred in the rabbit vulva and vagina, and vaginal and cervical secretions contained a large number of infectious pathogens, indicating that the rabbit bacterial vaginitis model was successfully prepared.

[0056] After flushing the rabbit vagina three times with 0.01 ml / L phosphate buffer, 0.2 ml of Candida albicans suspension was injected into the rabbit cervix through the catheter once a day for three consecutive days. The redness and swelling of the vulva and vagina, as well as the presence of secretions, were checked. Vaginal swabs were taken to obtain vaginal and cervical secretions for smear staining and microscopic examination. When the rabbit vagina was obviously congested, red and swollen with a large amount of purulent secretions, and a large number of infected bacteria were visible under microscopic examination, it was indicated that the rabbit fungal vaginitis model was successfully prepared.

[0057] 1.2 Trial Grouping and Dosing Regimen

[0058] 60 rabbits with bacterial vaginitis model were randomly divided into a model group and test groups 1-5 of the present invention by digital method, with 10 rabbits in each group. The model group was given sterile physiological saline, and the test groups 1-5 were given the private protection gel prepared by Examples 1-5 of the present invention by micro-syringe at a dose of 0.2g gel / kg weight, so that it was evenly distributed in the vagina and cervix, once a day, for 7 consecutive days. The general behavior, vulva status and secretions of the animals were observed daily. The rabbits were killed by gas embolism 24h after the last administration, and the vaginal tissue was fixed with 10% neutral formaldehyde, paraffin-wrapped, sliced, and HE-stained for pathological examination. Vaginal tissue biopsy pathological scoring and grading diagnostic criteria: Grading is based on the four basic indicators of congestion, edema, bleeding, and inflammatory cell infiltration. No congestion and edema is (-), mild is (+), moderate is (++), and severe is (+++). According to the pathological grading, (-) is 0 points, (+) is 1 point, (++) is 2 points, and (+++) is 3 points. According to the pathological grade points of the model rabbits in each test group after treatment, the therapeutic effect of the private care gel of the present invention on bacterial vaginitis was investigated.

[0059] In addition, 60 rabbits with candidal vaginitis model were taken, and the therapeutic effect of the private care gel of the present invention on candidal vaginitis was investigated by referring to the grouping scheme, administration method and experimental method of the above-mentioned rabbits with bacterial vaginitis model.

[0060] 2. Test results

[0061] The effects of the private care gel preparation of the present invention on the rabbit models of bacterial and fungal vaginitis are shown in Tables 1 and 2.

[0062] Table 1 Pathological scoring results of the gel preparation of the present invention on rabbits with bacterial vaginosis

[0063]

[0064] Table 2 Pathological scoring results of the gel preparation of the present invention on rabbits with fungal vaginitis

[0065]

[0066] The test results in Tables 1 and 2 above show that the pathological grade scores of rabbits with bacterial and fungal vaginitis after treatment with the private care gel of the test groups 1-5 of the present invention are significantly lower than those of the model group (the scores are significantly different compared with the model group), indicating that the private care gel of the present invention can effectively treat gynecological diseases such as vaginitis. Especially when the total amount of active ingredients remains unchanged (the total amount of the three active ingredients is 1g / 100g of gel preparation), the therapeutic effect of the private care gel (test group 1) containing lysozyme, sophanol and oxymatrine in a weight ratio of 1:1:2 is even better than that of preparations with other ratios (test groups 2-5), producing unexpected excellent effects.

[0067] Test Example 2 Study on the chemical stability of the private protection gel preparation of the present invention

[0068] 1. Test methods

[0069] This experiment sets up 5 test groups, among which test groups 1-3 use the private protection gel preparations of the present invention prepared in Examples 1 and 4-5, respectively, and test groups 4-5 use the private protection gel preparations prepared in Comparative Examples 1-2, and each test group repeats 3 samples. The above 5 test groups were stored at 60°C and 75% RH for 10 days, and the contents of scutellaria baicalensis and oxymatrine in the preparations of each test group were measured after being taken out, and the average contents of scutellaria baicalensis and oxymatrine in each test group after being placed were calculated.

[0070] 2. Test results

[0071] The average values ​​of scutellarin and oxymatrine contents in each test group are shown in Table 3 below.

[0072] Table 3 Contents of scutellarin and oxymatrine in the private care gel preparation of the present invention under high temperature and high humidity

[0073] Experimental Group Sophora flavescens content (%) Oxymatrine content (%) Experimental Group 1 99.21% 99.08% Experimental Group 2 98.17% 97.35% Experimental Group 3 97.42% 98.39% Experimental Group 4 94.57% 93.75% Experimental Group 5 93.18% 94.06%

[0074] It can be seen from the data of active ingredient content in the above table that the contents of scutellarin and oxymatrine in the gel preparations of test groups 1-3 (Examples 1 and 4-5) were not significantly reduced after storage under high temperature and high humidity conditions, and the content of active ingredients was maintained at more than 97%. In comparison, poloxamer 188 was omitted in test group 4 (Comparative Example 1), and poloxamer 188 was replaced with an equal amount of poloxamer 407 in test group 5 (Comparative Example 2). After storage, the contents of scutellarin and oxymatrine in the gel preparations were less than 95%, indicating that a large amount of impurities were generated in both active ingredients during storage, and the stability was poor. The above comparative test results show that the gel matrix selected by the present invention can effectively inhibit the generation of scutellarin and oxymatrine impurities, and it is expected that the gel preparation of the present invention has good stability during production and storage.

Claims

1. A private care gel preparation, characterized in that: The weight ratio of the active ingredients lysozyme, sophora japonicus and oxymatrine is 1:1:

2.

2. The private care gel preparation according to claim 1, characterized in that: The private care gel preparation further includes a pharmaceutically acceptable excipient, and the pharmaceutically acceptable excipient is selected from one or more of a gel base, a moisturizer, a solubilizer and a solvent.

3. The private care gel preparation according to claim 2, characterized in that: The gel matrix is ​​selected from one or more of sodium carboxymethylcellulose, carbomer, poloxamer and hydroxypropyl methylcellulose.

4. The private care gel preparation according to claim 3, characterized in that: The gel matrix is ​​a composition of sodium carboxymethylcellulose and poloxamer.

5. The private care gel preparation according to claim 4, characterized in that: The gel matrix is ​​a composition of sodium carboxymethylcellulose and poloxamer 188, and the weight ratio of sodium carboxymethylcellulose to poloxamer 188 is 8:

1.

6. The private care gel preparation according to claim 2, characterized in that: The humectant is glycerin or propylene glycol.

7. The private care gel preparation according to claim 2, characterized in that: The solubilizing agent is Tween 80 or Tween 60.

8. The method for preparing the private protection gel preparation according to any one of claims 2 to 7, characterized in that: The steps include: (1) Evenly mixing lysozyme, sophanol and oxymatrine with a solubilizer to obtain a drug solution; (2) adding a moisturizer to the gel matrix, mixing well, and then mixing well with the drug solution prepared in step (1); (3) Add a solvent to the solution obtained in step (2), stir to swell, and let stand for 24 hours to obtain the product.

9. Use of the private care gel preparation according to any one of claims 1 to 7 in the preparation of drugs for inhibiting bacteria and / or fungi.

10. A gel matrix composition for use in improving the chemical stability of the private protection gel preparation according to any one of claims 1 to 7, characterized in that: The gel matrix composition is sodium carboxymethyl cellulose and poloxamer 188 in a weight ratio of 8:1, and improving the chemical stability of the private protection gel preparation refers to simultaneously reducing the amount of scutellaria baicalensis and oxymatrine impurities generated in the preparation.